Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 4/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6725864 | 0.69 | SLC6A2 (0.36) | ASAH1SIGMAR1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL3039348 | 0.67 | MAOA (0.36) | LMNA | |
| SCHEMBL6728469 | 0.65 | TUBB4A (0.32) | — | |
| SCHEMBL14016380 | 0.64 | HPGD (0.44) | ASAH1LMNAKMT2A | |
| SCHEMBL16997521 | 0.63 | MIF (0.51) | ASAH1KMT2A | |
| SCHEMBL12049099 | 0.62 | NPC1 (0.50) | ASAH1SIGMAR1LMNAKMT2AHTT | |
| SCHEMBL14016382 | 0.58 | IDO1 (0.53) | — | |
| SCHEMBL12049010 | 0.58 | MAPK1 (0.53) | LMNA | |
| SCHEMBL12049104 | 0.55 | SIGMAR1 (0.41) | ASAH1SIGMAR1LMNAKMT2A | |
| SCHEMBL12245375 | 0.55 | NPC1 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | ASAH1 2717/4885SIGMAR1 1597/4885LMNA 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.